Annovis Bio, Inc., a clinical stage drug platform company, focuses on developing compounds to address neurodegeneration. The company's lead compound is ANVS-401, which is in Phase 2a clinical trials for the treatment of chronic neurodegenerative diseases, such as Down syndrome, Alzheimer's disease (AD), and Parkinson's disease. It is also developing ANVS-301, a compound in Phase 1 clinical trials to increase cognitive capability in later stages of AD and dementia; and ANVS-405, which is in preclinical study for protecting the brain after traumatic brain injury and/or stroke. Annovis Bio, Inc. was formerly known as QR Pharma, Inc. and changed its name to Annovis Bio, Inc. in March 2019. The company was founded in 2008 and is based in Berwyn, Pennsylvania.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone610-727-3913
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees2
Next Earnings DateN/A
OptionableNot Optionable
Annovis Bio (NYSE:ANVS) Frequently Asked Questions
What is Annovis Bio's stock symbol?
Annovis Bio trades on the New York Stock Exchange (NYSE) under the ticker symbol "ANVS."
Has Annovis Bio been receiving favorable news coverage?
Media coverage about ANVS stock has been trending negative this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Annovis Bio earned a news sentiment score of -2.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Annovis Bio.
Who are some of Annovis Bio's key competitors?
Some companies that are related to Annovis Bio include Verastem (VSTM), Paratek Pharmaceuticals (PRTK), NuCana (NCNA), Strongbridge Biopharma (SBBP), IDEAYA Biosciences (IDYA), Northwest Biotherapeutics (NWBO), Obseva (OBSV), Harrow Health (HROW), CELYAD SA/ADR (CYAD), Aptinyx (APTX), Newron Pharmaceuticals (NWPHF), Aravive (ARAV), ProMetic Life Sciences (PFSCF), Cassava Sciences (SAVA) and Millendo Therapeutics (MLND).
What other stocks do shareholders of Annovis Bio own?
Who are Annovis Bio's key executives?
Annovis Bio's management team includes the folowing people:
- Dr. Maria L. Maccecchini, Founder, CEO, Pres & Director (Age 69)
- Mr. Jeffrey B. McGroarty CPA, Chief Financial Officer (Age 51)
- Dr. Jeffrey L. Cummings, Chief Medical Officer & Member of Scientific Advisory Board (Age 70)
- Dr. William C. Mobley, Chief Scientific Advisor & Member of Scientific Advisory Board
When did Annovis Bio IPO?
(ANVS) raised $10 million in an initial public offering (IPO) on Wednesday, January 29th 2020. The company issued 1,400,000 shares at a price of $6.00-$8.00 per share. ThinkEquity (a division of Fordham Financial Management, Inc. ) acted as the underwriter for the IPO.
When does Annovis Bio's quiet period expire?
Annovis Bio's quiet period expires on Monday, March 9th. Annovis Bio had issued 2,000,000 shares in its public offering on January 29th. The total size of the offering was $12,000,000 based on an initial share price of $6.00. During Annovis Bio's quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.
How do I buy shares of Annovis Bio?
Shares of ANVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Annovis Bio's stock price today?
One share of ANVS stock can currently be purchased for approximately $4.79.
How big of a company is Annovis Bio?
What is Annovis Bio's official website?
How can I contact Annovis Bio?
Annovis Bio's mailing address is 1055 WESTLAKES DRIVE SUITE 300, BERWYN PA, 19312. The company can be reached via phone at 610-727-3913 or via email at [email protected]
MarketBeat Community Rating for Annovis Bio (NYSE ANVS)
MarketBeat's community ratings are surveys of what our community members think about Annovis Bio and other stocks. Vote "Outperform" if you believe ANVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
